IMMP — IMMUTEP Ltd

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1506184 ·
Last close
$3.26
Market Cap
$480.43M
52W High
$64.60
52W Low
$1.67
ADV30
25,422
Next earnings
2026-09-03

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 — — — — 83,267,229 63,672,558 21,734,183
Mar 2026 — — — — — — —
Dec 2025 — — — — 147,201,896 72,747,858 48,303,108
Mar 2025 — — — — — — —

Balance + Analyst (yfinance extras)

Retained Earnings
$-520,796,399
Inventory
—
Receivables
$9,623,374
ST Investments
$5,200,486
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
1

Yahoo Snapshot (yfinance, live)

Total Revenue
$19,934,102
EBITDA
$-79,403,952
Free Cash Flow
$-36,994,360
Enterprise Value
$-12,811,502
Total Cash
$68,873,040
Total Debt
$1,047,526
Shares Out
147,372,131
Trailing EPS
$-0.39
Book Value
$0.30
ROE
-77.3%
ROA
-42.5%
Div Yield
—

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Jun 2026 14,556,923 -81,592,146 -79,304,563 83,267,229 21,734,183 61,533,046 —
Jun 2025 — — — — — — —
Jun 2024 0 -46,557,462 -42,716,625 201,579,281 12,057,539 189,521,742 —
Jun 2023 0 -41,431,305 -39,896,348 147,448,990 10,979,601 136,469,389 —
Jun 2022 170,369 -33,837,338 -32,210,826 102,169,550 8,092,184 94,077,366 -43,944,386

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.26

Peers — same industry

TickerNameMarket CapLastDaily %
BLSM BlossomHill Therapeutics, Inc. $480.91M $15.13 —
MNPR Monopar Therapeutics $481.56M $71.06 —
NGNE Neurogene Inc. $478.19M $23.10 —
AMRN AMARIN CORP PLC\UK $473.82M $11.27 —
GYRE GYRE THERAPEUTICS, INC. $488.23M $4.56 —

News headlines (Yahoo Finance, 1h cache)

Immutep Reports Encouraging Disease-Free Survival from EFTISARC-NEO Phase II Trial in Soft Tissue Sarcoma
2026-11-19 00:12 · Yahoo
Immutep Further Expands United States Patent Estate for Efti-Based Combination Therapies
2026-11-10 23:48 · Yahoo
IMP761 Late-Breaking Abstract at ACR Convergence 2026 Highlights Statistically Significant & Exposure-Dependent Inhibition of T-Cell-Driven Immune Responses
2026-11-08 22:34 · Yahoo
Immutep Announces Upcoming Poster Presentations at CTOS 2026 and ESMO Immuno-Oncology & Advanced Therapies Congress 2026
2026-11-05 13:00 · Yahoo
Immutep Quarterly Activities Report Q1 FY27
2026-10-29 12:00 · Yahoo
Immutep Receives A$2.16 million French R&D Tax Incentive
2026-10-28 12:00 · Yahoo
Immutep Announces Presentation of Quality of Life Data from EFTISARC-NEO Phase II Trial at ESMO 2026
2026-10-23 12:00 · Yahoo
Immutep Announces Late-Breaking Abstract on IMP761 Accepted for Poster Presentation at ACR Convergence 2026
2026-10-19 12:00 · Yahoo
Immutep and Monash University Secure Further ARC Linkage Projects Funding for LAG-3 Research
2026-10-14 12:00 · Yahoo
Immutep Regains Compliance with Nasdaq Minimum Bid Price Requirement
2026-10-13 12:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.